DekaBank Deutsche Girozentrale lifted its holdings in Amgen, Inc. (NASDAQ:AMGN) by 34.0% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,153,511 shares of the medical research company’s stock after purchasing an additional 292,548 shares during the period. Amgen comprises 1.1% of DekaBank Deutsche Girozentrale’s holdings, making the stock its 17th biggest holding. DekaBank Deutsche Girozentrale’s holdings in Amgen were worth $212,628,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also made changes to their positions in AMGN. Geode Capital Management LLC increased its position in shares of Amgen by 5.8% in the fourth quarter. Geode Capital Management LLC now owns 8,850,224 shares of the medical research company’s stock worth $1,720,250,000 after acquiring an additional 482,760 shares in the last quarter. Norges Bank purchased a new position in shares of Amgen in the fourth quarter worth approximately $1,283,248,000. Nordea Investment Management AB increased its position in shares of Amgen by 5.0% in the first quarter. Nordea Investment Management AB now owns 4,709,467 shares of the medical research company’s stock worth $894,700,000 after acquiring an additional 225,485 shares in the last quarter. Legal & General Group Plc increased its position in shares of Amgen by 5.7% in the fourth quarter. Legal & General Group Plc now owns 3,241,580 shares of the medical research company’s stock worth $631,039,000 after acquiring an additional 174,360 shares in the last quarter. Finally, Two Sigma Advisers LP boosted its holdings in shares of Amgen by 18.0% during the fourth quarter. Two Sigma Advisers LP now owns 2,069,296 shares of the medical research company’s stock worth $402,830,000 after purchasing an additional 315,600 shares during the period. 78.96% of the stock is currently owned by institutional investors.
In other news, Director R Sanders Williams sold 425 shares of the business’s stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $183.04, for a total value of $77,792.00. Following the completion of the sale, the director now directly owns 16,336 shares in the company, valued at $2,990,141.44. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Ronald D. Sugar sold 2,000 shares of the business’s stock in a transaction on Wednesday, July 3rd. The stock was sold at an average price of $187.58, for a total transaction of $375,160.00. Following the completion of the sale, the director now owns 16,336 shares of the company’s stock, valued at $3,064,306.88. The disclosure for this sale can be found here. Insiders sold 4,425 shares of company stock valued at $804,312 over the last quarter. Corporate insiders own 0.25% of the company’s stock.
Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, July 30th. The medical research company reported $3.97 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $3.58 by $0.39. The firm had revenue of $5.87 billion during the quarter, compared to analysts’ expectations of $5.67 billion. Amgen had a net margin of 33.78% and a return on equity of 76.17%. The company’s revenue was down 3.1% compared to the same quarter last year. During the same period in the previous year, the company earned $3.83 earnings per share. On average, analysts expect that Amgen, Inc. will post 14.23 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, September 6th. Shareholders of record on Thursday, August 15th will be paid a $1.45 dividend. This represents a $5.80 dividend on an annualized basis and a yield of 2.81%. The ex-dividend date is Wednesday, August 14th. Amgen’s dividend payout ratio (DPR) is presently 40.28%.
Several analysts recently commented on the stock. Evercore ISI restated a “hold” rating on shares of Amgen in a report on Sunday. Mizuho restated a “buy” rating and set a $208.00 price target on shares of Amgen in a report on Monday, July 1st. JPMorgan Chase & Co. restated a “hold” rating on shares of Amgen in a report on Friday, August 9th. BidaskClub upgraded shares of Amgen from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Finally, BMO Capital Markets set a $230.00 price target on shares of Amgen and gave the stock a “buy” rating in a report on Wednesday, July 31st. Nine analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $211.78.
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.
Featured Article: What are no-load funds?
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.